Insider filing · ACAD
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
profile →
ACADIA Pharmaceuticals Inc.
ACAD · Healthcare · 12 filings in 24 months
ticker →
Mark C. Schneyer sold $554K of ACADIA Pharmaceuticals (ACAD)
Executed Aug 18 2025, disclosed Aug 19 2025, 1 day later.
Value, as filed
$554K
22,000 sh × $25.18
Executed
Aug 18 2025
the trade date, as filed
Disclosed
Aug 19 2025
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MSMark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in ACADIA Pharmaceuticals Inc. (ACAD). The largest single filing was $587K of ACAD (20,141 sh across 3 lots, as filed), executed Aug 5.
The name
ACADHealthcare · ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological an…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Mark C. Schneyer in ACAD
ACADSALE
ACADIA Pharmaceuticals Inc.
$587K20,141 sh across 3 lots
Exec Aug 5
Filed Aug 7 · 6:00 PM ET ACADSALE ACADIA Pharmaceuticals Inc. $243K
10,262 sh × $23.69
Exec Nov 18 2025
Filed Nov 19 2025 · 5:30 PM ET ACADSALE ACADIA Pharmaceuticals Inc. $172K
10,259 sh × $16.81
Exec Nov 19 2024
Filed Nov 19 2024 · 5:30 PM ET